Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Olix initiates phase II study of OLX-10010 as treatment of hypertrophic scars

May 21, 2021

China's NMPA approves phase I trial of InnoCare's TYK2 inhibitor ICP-332

May 19, 2021

Phase III trials of ruxolitinib in vitiligo meet endpoints

May 17, 2021

Dosing begins in phase II trial of CGB-400 for rosacea

May 14, 2021

Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis

May 12, 2021

GBR-830 shows improvement at 16 weeks in patients with moderate to severe atopic dermatitis

May 11, 2021

Topline phase IIa data reported on FOL-005 for alopecia

May 7, 2021

Aslan Pharmaceuticals presents phase I data for the IL13RA1 inhibitor ASLAN-004

May 7, 2021

BioCryst Pharmaceuticals patent details complement factor D inhibitors

May 6, 2021

BioCryst Pharmaceuticals presents complement factor D inhibitors

May 5, 2021

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...